ABSTRACT
Background: Metformin is believed that marvelous survivor for diabetes and coined as glucose eater among all oral hypoglycemic agents. Antibiotic Resistance is the major issue which compromising the treatment of bacterial, viral, fungal, parasitic infection. The present study showed that effectiveness of metformin drug on microbes. Methods: This study conducted in the department of pharmacology in the carrier institute of medical sciences over a period of six month. Results: Antimicrobial activity of metformin was evaluated against Gram-positive, Gram-negative bacteria and fungi using disk diffusion technique of Kierby baur methods. CIP & AK was used as standard antibiotics. Antioxidant potentiality of metformin was investigated by DPPH scavenging activity. Metformin active at 500 μg/ml, showed very good antimicrobial activity against most of the bacterial strains with an average zone of inhibition of 12-15mm. Conclusions: Metformin demonstrated a pronounced inhibitory action against Pseudomonas aeruginosa, an organism which is known to be multidrug resistant. The tested fungi are Candida albicans and Aspergillus niger. The tested drug showed very good antifungal activity with an average 13-17 mm zone of inhibition.
ABSTRACT
Acne vulgaris is one of the commonest skin disorders that can affect individuals from childhood to adulthood, most often occurring in the teenage years. Regarding its management, what’s still true is that a wide range of treatment options are available, ranging from the commonly used topical treatments like benzoyl peroxide, azelaic acid, sulfur, antibiotics, retinoids and superficial chemical peels while the systemic treatments available include the use of systemic antibiotics, retinoids, and antiandrogens. What’s new in the management of acne vulgaris is the use of laser and light devices and other newer technologies. The present article reviews the use of above mentioned agents in the current scenario.
ABSTRACT
Background and Objective: Clinical trials have shown the potential use of 5-HT3 receptor antagonists like Ondansetron, Tropisetron and Zacopride in a number of disorders of gastrointestinal tract and the central nervous system such as cancer chemotherapy induced vomiting, anxiety, depression, schizophrenia and migraine. Various experimental and clinical studies also point the usefulness of Ondansetron in neuropathic pain. Therefore, the present study was conducted to find out whether Ondansetron could be used as an alternative to a standard drug, Amitriptyline in the treatment of peripheral neuropathy. Methodology: A randomized double blind prospective clinical study was conducted on Original Research Article British Journal of Medicine & Medical Research, 4(26): 4444-4454, 2014 4445 thirty six patients of peripheral neuropathy divided into two groups of equal number of patients. Group 1 received Ondansetron 8 mg per day while Group 2 received Amitriptyline 25 mg per day. Patients were being evaluated on the basis of improvements (decrease) in LANSS (Leeds Assessment of Neuropathic Symptoms and Signs), VAS (Visual Analogue Scale) and NCV (Nerve Conduction Velocity) for six weeks. Student’s ttest and/or repeated measure ANOVA followed by Bonferoni correlation was used to compare sets of paired observations. The Friedman test followed by multiple comparisons was used to compare the data which was not normally distributed. Results: LANSS and VAS scores showed significant improvements in the 1st and 2nd visit in both the groups. NCV showed improvement in Ondansetron group with less number of adverse effects compared to that of Amitriptyline. NCV in Amitriptyline group demonstrated significant increase in one of the parameters, F-waves, indicating a worsening in left tibial nerve (p=0.036), whereas no such change was found in the group treated with Ondansetron. Conclusion: Ondansetron has beneficial role in peripheral neuropathy by improving its sensory component as it significantly decreased LANSS and VAS scores. Our results also demonstrated that Ondansetron was at least as efficacious as Amitriptyline in the treatment of peripheral neuropathy with lesser adverse effects.